It is no surprise that inequalities, especially in health, are increasing. Wealth is health as the wealthiest are increasing their share of the world’s capital. Is their concern with investing in “unapproved” and “unproven” treatments driven by opportunism, an expression of guilt, or altruism? Who will be included and who will be excluded, and who will decide? NHSreality knows the money would be spent differently by Public Health consultants (populations), and that these people just cannot think of anything else/better to do with their wealth. What a shame when caring properly would give a better happiness dividend. They, like our politicians, won’t even realise reality when their own time comes as they will be fully cared for. It appears that, if commissioners wont’ provide in the state controlled lottery, private capital might, if you know the right people… in the post-truth world.
Credit NYT; Reuters; Reuters; Reuters; Getty; European Pressphoto Agency; Getty; AP
A Dutch company aiming to give doctors and their terminally ill patients access to drugs that have not won official approval has raised €10 million.
MyTomorrows seeks to benefit both patients who have run out of treatments options and drugs companies, which gain access to data and fees from selling small quantities of drugs that have passed initial tests but are not yet approved for sale or use where the patient lives. The start-up has compiled a global database of unapproved medicines and acts as a broker, helping to navigate protocols and regulations in different countries.
The problem of access to unapproved drugs was raised recently by AA Gill, the writer and restaurant critic, who died last month aged 62. In a final essay he revealed that the NHS had denied him a pioneering treatment for cancer recommended by “every oncologist in the first world” because of its cost of up to £100,000 a year.
Ronald Brus founded myTomorrows three years ago after his father developed cancer and ran out of treatment options. As the former chief executive of Crucell, a vaccine company that Johnson & Johnson bought in 2010 for $2.4 billion, Mr Brus started calling big pharmaceuticals companies to see if he could get access to drugs in development.
“I thought this is not really fair. I have the opportunity to do this because of my background, but other people do not,” he said.
So far, the company has provided hundreds of patients with access to treatments, which have been paid for by insurers. The company said that in Britain most treatments it had provided had been paid for by the NHS, with the remainder funded by private insurance.
The latest funding round is being led by the London-based Octopus Ventures, which previously has invested in Zoopla, LoveFilm, SwiftKey and Magic Pony, and EQT Ventures, a Stockholm-based fund.
MyTomorrows raised €4.5 million in 2014 in its first institutional financing.
World’s 8 richest men are worth as much as 3.6 billion people – The Telegraph